​oligoDOM® (OVX313) is derived from our first generation technology (IMX313). The technology has been improved with the addition of a highly positively charged polyarginine tail to facilitate entry in dendritic cells and elicit much higher CD8 T-cell responses​oligoDOM® (OVX313) technology platform:

is a versatile technology that can be used with a full antigen or a long peptide